Literature DB >> 19162082

Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.

Gunnar Thiemann1, Carly A Watt, Catherine Ledent, Areles Molleman, Rüdiger U Hasenöhrl.   

Abstract

The CB(1) cannabinoid receptor has been implicated in the control of fear and anxiety. We investigated the effects of genetic and pharmacological blockade of the CB(1) cannabinoid receptor on the behaviour of CD1 mice using three different ethological models of fear and anxiety (elevated T-maze and plus-maze and open field test of emotionality). Furthermore, we measured tissue levels of noradrenalin (NA), dopamine (DA), serotonin (5-HT) and their metabolites in several forebrain regions, i.e. prefrontal cortex, hippocampus, septum, dorsal and ventral striatum to examine the relationship between CB(1) receptor manipulation and monoaminergic neurotransmission. The major findings can be summarized as follows: the CB(1) receptor antagonist SR141617A (rimonabant) modulated anxiety in a dose-dependent manner. At a dose of 3 mg/kg i.p., the compound consistently increased anxiety parameters in all of the three different anxiety tests applied, while a lower dosage of 1mg/kg had no such effect. The neurochemical evaluation of the mice administered 3mg/kg SR141617A revealed increases in the concentrations of DOPAC and 5-HIAA in the dorsal striatum, elevated DA levels in the hippocampus and reduced dopamine turnover in the septum. Furthermore, these animals had a higher HVA/DA turnover in the frontal cortex. CB(1) receptor knockout mice as well as mice treated with the selective CB(1) receptor antagonist AM251 (3 mg/kg; i.p.) did not display any significant alterations in anxiety-related behaviour as measured with the elevated plus-maze and open field test of emotionality, respectively. Our findings support the general idea of a SR141617A-sensitive receptive site that is different from the 'classical' CB(1) receptor and that has a pivotal role in the regulation of different psychological functions. However, with regard to its functional significance in terms of anxiety our findings suggest that under physiological conditions this receptive site seems to be involved in the control of anxiolysis rather than anxiogenesis as suggested previously.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19162082     DOI: 10.1016/j.bbr.2008.12.035

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  11 in total

1.  Alterations in corticolimbic dendritic morphology and emotional behavior in cannabinoid CB1 receptor-deficient mice parallel the effects of chronic stress.

Authors:  Matthew N Hill; Cecilia J Hillard; Bruce S McEwen
Journal:  Cereb Cortex       Date:  2011-01-24       Impact factor: 5.357

2.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

3.  Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm.

Authors:  Andrés Uribe-Mariño; Audrey Francisco; Maria Angélica Castiblanco-Urbina; André Twardowschy; Carlos José Salgado-Rohner; José Alexandre S Crippa; Jaime Eduardo Cecílio Hallak; Antônio Waldo Zuardi; Norberto Cysne Coimbra
Journal:  Neuropsychopharmacology       Date:  2011-09-14       Impact factor: 7.853

Review 4.  Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.

Authors:  Matthew N Hill; Patrizia Campolongo; Rachel Yehuda; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2017-07-26       Impact factor: 7.853

5.  Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.

Authors:  Elizabeth J Rahn; Ganesh A Thakur; Jodi Anne T Wood; Alexander M Zvonok; Alexandros Makriyannis; Andrea G Hohmann
Journal:  Pharmacol Biochem Behav       Date:  2011-03-05       Impact factor: 3.533

6.  Concentration, population, and context-dependent effects of AM251 in zebrafish.

Authors:  Steven Tran; Diptendu Chatterjee; Amanda Facciol; Robert Gerlai
Journal:  Psychopharmacology (Berl)       Date:  2016-02-16       Impact factor: 4.530

7.  The clinical implications of mouse models of enhanced anxiety.

Authors:  Simone B Sartori; Rainer Landgraf; Nicolas Singewald
Journal:  Future Neurol       Date:  2011-07-01

8.  Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.

Authors:  David R Powell; Jason P Gay; Nathaniel Wilganowski; Deon Doree; Katerina V Savelieva; Thomas H Lanthorn; Robert Read; Peter Vogel; Gwenn M Hansen; Robert Brommage; Zhi-Ming Ding; Urvi Desai; Brian Zambrowicz
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-02       Impact factor: 5.555

9.  Interaction Between the Cannabinoid and Vanilloid Systems on Anxiety in Male Rats.

Authors:  Nafiseh Faraji; Alireza Komaki; Iraj Salehi
Journal:  Basic Clin Neurosci       Date:  2017 Mar-Apr

10.  Toluene Inhalation Causes Early Anxiety and Delayed Depression with Regulation of Dopamine Turnover, 5-HT1A Receptor, and Adult Neurogenesis in Mice.

Authors:  Jinhee Kim; Juhee Lim; Seong-Hee Moon; Kwang-Hyeon Liu; Hyun Jin Choi
Journal:  Biomol Ther (Seoul)       Date:  2020-05-01       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.